SCHEMBL4313730

SCHEMBL4313730

CC(C)=CC(SC(C=C(C)C)c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.41
ALDH1A1 P00352 1/20 0.38
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
HBB P68871 1/20 0.35
KMT2A Q03164 1/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2C P18825 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HIF1A Q16665 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9189816 0.83 ESR1 (0.44) ALDH1A1LMNAMEN1HBBKMT2A
SCHEMBL8565962 0.79 ACHE (0.41) ALDH1A1LMNATDP1IDO1
SCHEMBL9006991 0.77 IDO1 (0.40) ALDH1A1MEN1KMT2AIDO1TDO2
SCHEMBL4945391 0.76 TRPA1 (0.42) TRPA1ALDH1A1LMNAADRA2AADRA2C
SCHEMBL8566368 0.75 PTGS2 (0.39) TRPA1TDP1IDO1TDO2
SCHEMBL1305172 0.75 TRPA1 (0.45) TRPA1ALDH1A1LMNAADRA2AADRA2C
SCHEMBL6935686 0.75 TRPA1 (0.45) TRPA1ALDH1A1LMNAADRA2AADRA2C
SCHEMBL9222442 0.73 TRPA1 (0.64) TRPA1ALDH1A1LMNAADRA2AADRA2C
SCHEMBL4641824 0.73 TRPA1 (0.44) TRPA1ALDH1A1LMNAMEN1HBB
SCHEMBL8565354 0.73 DRD2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO claimed
WO-2006059345-A3 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2009-10-15 WO disclosed
US-7414143-B2 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (IN) 2008-08-19 US disclosed
US-20070238881-A1 Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene GLENMARK PHARMACEUTICALS LIMITED (IN) 2007-10-11 US disclosed
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO disclosed
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO disclosed
US-20060106233-A1 Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-05-18 US disclosed
WO-2005123713-A1 PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS GLENMARK PHARMACEUTICALS LIMITED (US) 2005-12-29 WO disclosed
US-6963002-B2 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (US) 2005-11-08 US disclosed
US-20050240029-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (IN) 2005-10-27 US disclosed
US-5234926-A Skin disorders ALLERGAN, INC. (US) 1993-08-10 US disclosed
EP-0284288-B1 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY ALLERGAN, INC (US) 1992-05-27 EP disclosed
US-5089509-A Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC. (US) 1992-02-18 US disclosed
EP-0290130-B1 ACETYLENES DISUBSTITUTED WITH A PHENYL GROUP AND A HETEROBICYCLIC GROUP HAVING RETINOID LIKE ACTIVITY ALLERGAN, INC (US) 1991-11-06 EP disclosed
US-5053523-A Chemical intermediate for compounds having retinoic acid-like activity ALLERGAN, INC. (US) 1991-10-01 US disclosed
US-5023341-A Acetylene thiochroman ALLERGAN, INC. (US) 1991-06-11 US disclosed
EP-0419132-A2 Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity ALLERGAN, INC. (US) 1991-03-27 EP disclosed
US-4810804-A PSORIASIS ALLERGAN, INC. (US) 1989-03-07 US disclosed
EP-0290130-A1 Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity ALLERGAN, INC (US) 1988-11-09 EP disclosed
EP-0284288-A1 Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC (US) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238881-A1 Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene NAMPT, NAPRT, NNT TRPA1 3457/4885ALDH1A1 1128/4885LMNA 2224/4885
US-20050240029-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman YAP1, SDHA, SDHB TRPA1 1258/4885ALDH1A1 603/4885LMNA 2438/4885
US-20060106233-A1 Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups CBR3, NR1H2, NR3C2 TRPA1 2131/4885ALDH1A1 2258/4885LMNA 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.